Peptela

The catalogue is compounded prescriptions. Tirzepatide and semaglutide in injected, oral and lower-dose forms; sermorelin; NAD+; glutathione; a lipotropic B12 injection; a GHK copper peptide cream; an oxytocin and PT-141 tablet; four oral hair-growth tablets; and an estradiol and progesterone cream. Each is sold as a monthly subscription, and each product page marks it “Rx”.

Compounded drugs are not FDA-approved. Peptela’s own terms say so in the same words: “Compounded medications are not FDA-approved and are not evaluated by the FDA for safety, effectiveness, or quality.” That is a different regulatory status from an FDA-approved drug, and a different thing again from the research-use-only material sold by the vendors listed under All Vendors. Nothing on this page is medical advice, and nothing here says any treatment is appropriate for any particular reader — that is what the provider review is for.

1. An online intake. Lifestyle, health and medical history, submitted through a form in Peptela’s patient portal at my.peptela.com. Peptela describes the visit as 100% online with no waiting room.
2. A provider reviews it. Peptela’s terms say licensed medical providers decide whether treatment is appropriate, and that submitting an intake or completing checkout does not guarantee approval. Peptela describes the reviewers as its “in-house licensed clinicians”; its Medical Consent says a provider-patient relationship, if one is established, is determined by “the licensed provider or provider network involved”. No prescriber or provider network is named, and Prof. Peptide has read no licence or credential for any of them.
3. A pharmacy dispenses and ships. Peptela states that approved treatments are compounded by a “US-licensed, LegitScript-certified pharmacy partner” and shipped within 5–7 business days. The pharmacy is not named, and the certification is Peptela’s statement, not something Prof. Peptide has checked.
4. Ongoing contact. Peptela lists provider messaging, refills, check-ins and dosage adjustments as part of the subscription.

Shipping

Every product page lists “Free, discreet shipping.”

HSA and FSA

Every product page carries an “HSA / FSA” label. That is Peptela’s statement about its own billing, not something Prof. Peptide has tested.

Plan lengths

Every product page lists “Monthly, 3-mo, and 6-mo plans,” but no page publishes a 3-month or 6-month price.

Payment before approval

Peptela’s refund policy says submitting payment does not guarantee approval, and that if a provider decides treatment is not appropriate it “may provide a refund or alternative resolution” depending on services already rendered and any fees.

Cancelling

Product pages say “Pause or cancel anytime.” The refund policy adds that subscriptions may renew on the billing terms shown at checkout, that cancelling before renewal is the subscriber’s responsibility, and that once a refill has been processed or shipped, refunds may be limited or unavailable.

“Starting at” is the only figure published. The 3-month and 6-month plans each page mentions carry no published price, and checkout sits behind the intake, so Prof. Peptide has not seen what a longer plan costs. Nothing here is averaged or derived.

Prices are Peptela’s and change without notice to Prof. Peptide. The date above is the date Prof. Peptide read them, not a promise about today.

The GLP-1 treatments sit in a changed landscape. FDA determined the tirzepatide injection shortage resolved on 19 December 2024 and the semaglutide injection shortage resolved on 21 February 2025, and the period of enforcement discretion for 503A compounding of semaglutide ended on 28 April 2025. FDA states that when a shortage is resolved it generally considers the drug commercially available, and section 503A restricts compounding drugs that are essentially copies of a commercially available drug product. Prof. Peptide draws no conclusion from that — whether a given preparation is essentially a copy turns on a prescriber’s determination that Prof. Peptide cannot see. It is reported here because the dates are public and material. Sermorelin has no listing determination or categorisation in FDA’s bulk-substance categories for 503A compounding.

• The link on this page goes where it says. Every button here points at Prof. Peptide’s own redirect, /go/peptela, whose destination is the referral URL Peptela’s affiliate program issued, byte-for-byte. Requested directly, that URL redirects from peptela.com to www.peptela.com with the referral parameter intact and loads the homepage. Prof. Peptide adds no parameters of its own, and a build check refuses any link on this page that points anywhere else.
• Every price came off the treatment’s own page. All 48 URLs in Peptela’s sitemap were read, including all 26 treatment pages, and each figure in the table is the “Starting at” line on that treatment’s page. Peptela’s homepage refers to “40+ science-backed plans”; the sitemap lists 26 treatment pages, and those are what the table covers.
• The intake runs on a separate platform. Each treatment page’s “Get Started” button leads to an intake form at my.peptela.com, and that host is a DNS alias of Rimo, a white-label telehealth platform. The patient portal sits behind a sign-in, so no cart or checkout could be read.
• The legal documents name no company. The Terms & Conditions, Refund Policy, Medical Consent and Bill of Rights all carry an effective date of June 18, 2026, and each gives its contact as “Peptela” with help@peptela.com, (307) 302-4736 and 5830 E 2nd St, Ste 7000, Casper, WY 82609. No LLC, corporation or other legal entity is named. The domain peptela.com was registered on 22 April 2026, per its public registration record.
• The named doctors are content reviewers. Peptela’s About page names three physicians under the label “Medical Review Team” and describes the role in terms of medical review and educational content. The site does not say they prescribe.

What is not there to check. No prescriber, provider network or compounding pharmacy is named. No certificate of analysis is published and no testing laboratory is named, so there is no document to open. No list of the states served is published. The figures Peptela publishes about itself — member counts, review counts, satisfaction ratings, years of combined clinical experience and the share of members who notice a benefit — come with no source Prof. Peptide could read, so none of them is repeated on this page as fact.